Ghost Tree Capital as of June 30, 2017
Portfolio Holdings for Ghost Tree Capital
Ghost Tree Capital holds 63 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Portola Pharmaceuticals | 7.0 | $34M | 600k | 56.17 | |
| Clovis Oncology | 5.9 | $28M | 301k | 93.63 | |
| SPDR S&P Biotech (XBI) | 5.6 | $27M | 350k | 77.18 | |
| Alexion Pharmaceuticals | 3.7 | $18M | 145k | 121.67 | |
| Bristol Myers Squibb (BMY) | 3.5 | $17M | 300k | 55.82 | |
| Avexis | 3.2 | $16M | 190k | 82.16 | |
| Seattle Genetics | 3.2 | $16M | 300k | 51.74 | |
| Dbv Technologies S A (DBVT) | 3.1 | $15M | 425k | 35.71 | |
| Puma Biotechnology (PBYI) | 2.7 | $13M | 150k | 87.40 | |
| Merck & Co (MRK) | 2.7 | $13M | 200k | 64.09 | |
| Gw Pharmaceuticals Plc ads | 2.6 | $13M | 125k | 100.25 | |
| Nevro (NVRO) | 2.5 | $12M | 165k | 74.43 | |
| Immunomedics | 2.2 | $11M | 1.2M | 8.83 | |
| Zimmer Holdings (ZBH) | 2.1 | $10M | 80k | 128.40 | |
| GenMark Diagnostics | 2.0 | $9.8M | 825k | 11.83 | |
| Intra Cellular Therapies (ITCI) | 1.8 | $8.7M | 700k | 12.42 | |
| Endo International (ENDPQ) | 1.7 | $8.4M | 750k | 11.17 | |
| Juno Therapeutics | 1.7 | $8.2M | 275k | 29.89 | |
| Insmed (INSM) | 1.7 | $8.2M | 475k | 17.16 | |
| Acorda Therapeutics | 1.6 | $7.9M | 400k | 19.70 | |
| NuVasive | 1.6 | $7.7M | 100k | 76.92 | |
| Spectranetics Corporation | 1.6 | $7.7M | 200k | 38.40 | |
| ACADIA Pharmaceuticals (ACAD) | 1.6 | $7.7M | 275k | 27.89 | |
| Exelixis (EXEL) | 1.5 | $7.4M | 300k | 24.63 | |
| Enanta Pharmaceuticals (ENTA) | 1.5 | $7.2M | 200k | 35.98 | |
| Tesaro | 1.4 | $7.0M | 50k | 139.86 | |
| Neurocrine Biosciences (NBIX) | 1.4 | $6.9M | 150k | 46.00 | |
| NxStage Medical | 1.4 | $6.5M | 260k | 25.07 | |
| CurrencyShares British Pound Ster. Trst | 1.3 | $6.5M | 51k | 126.82 | |
| Irhythm Technologies (IRTC) | 1.3 | $6.4M | 150k | 42.49 | |
| Entellus Medical Cm | 1.3 | $6.2M | 375k | 16.56 | |
| Novadaq Technologies | 1.2 | $5.9M | 500k | 11.72 | |
| Nanostring Technologies (NSTGQ) | 1.2 | $5.8M | 350k | 16.54 | |
| Gilead Sciences (GILD) | 1.1 | $5.3M | 75k | 70.79 | |
| Kite Pharma | 1.1 | $5.2M | 50k | 103.68 | |
| Aimmune Therapeutics | 1.1 | $5.1M | 250k | 20.56 | |
| Atara Biotherapeutics (ATRA) | 1.0 | $4.9M | 350k | 14.00 | |
| Boston Scientific Corporation (BSX) | 1.0 | $4.9M | 175k | 27.72 | |
| Viewray (VRAYQ) | 1.0 | $4.9M | 750k | 6.47 | |
| Aquinox Pharmaceuticals | 0.9 | $4.2M | 300k | 14.07 | |
| Argenx Se (ARGX) | 0.9 | $4.2M | 196k | 21.21 | |
| Axovant Sciences | 0.8 | $4.1M | 175k | 23.19 | |
| Iovance Biotherapeutics (IOVA) | 0.8 | $4.0M | 550k | 7.35 | |
| Sage Therapeutics (SAGE) | 0.8 | $4.0M | 50k | 79.64 | |
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $3.8M | 675k | 5.56 | |
| Cymabay Therapeutics | 0.8 | $3.7M | 650k | 5.76 | |
| Ptc Therapeutics I (PTCT) | 0.8 | $3.7M | 200k | 18.33 | |
| K2m Group Holdings | 0.8 | $3.7M | 150k | 24.36 | |
| Neos Therapeutics | 0.8 | $3.7M | 500k | 7.30 | |
| Blueprint Medicines (BPMC) | 0.7 | $3.5M | 70k | 50.67 | |
| Rigel Pharmaceuticals (RIGL) | 0.6 | $3.0M | 1.1M | 2.73 | |
| Alder Biopharmaceuticals | 0.6 | $2.9M | 250k | 11.45 | |
| Syndax Pharmaceuticals (SNDX) | 0.6 | $2.8M | 200k | 13.97 | |
| Acceleron Pharma | 0.6 | $2.7M | 90k | 30.39 | |
| IRIDEX Corporation (IRIX) | 0.5 | $2.5M | 250k | 9.89 | |
| Revance Therapeutics (RVNC) | 0.5 | $2.4M | 89k | 26.40 | |
| Epizyme | 0.5 | $2.3M | 150k | 15.10 | |
| Quotient | 0.5 | $2.2M | 300k | 7.36 | |
| Spark Therapeutics | 0.4 | $2.1M | 35k | 59.74 | |
| Ra Pharmaceuticals | 0.3 | $1.6M | 85k | 18.74 | |
| Zogenix | 0.3 | $1.5M | 100k | 14.50 | |
| Audentes Therapeutics | 0.2 | $957k | 50k | 19.14 | |
| Foamix Pharmaceuticals | 0.1 | $580k | 125k | 4.64 |
